Squarepoint Ops LLC Invests $1.19 Million in Haleon PLC Sponsored ADR $HLN

Key Points

• Squarepoint Ops LLC acquired 127,143 Haleon shares during the second quarter, valued at approximately $1.19 million.
• Several major institutions increased their Haleon positions, including Arrowstreet Capital, Bank of America, Sculptor Capital and Goldman Sachs; institutional investors collectively own 6.67% of the company.
• HLN shares opened at $9.22, below their 50-day and 200-day moving averages. Analyst sentiment remains moderately bullish, with a consensus “Moderate Buy” rating despite some recent rating downgrades.

Squarepoint Ops LLC acquired a new position in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 127,143 shares of the company's stock, valued at approximately $1,186,000.

Other institutional investors have also recently bought and sold shares of the company. Norges Bank purchased a new position in Haleon in the fourth quarter valued at about $163,529,000. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Haleon by 82.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company's stock valued at $146,892,000 after buying an additional 6,647,329 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Haleon by 17.0% in the 1st quarter. Bank of America Corp DE now owns 10,934,228 shares of the company's stock valued at $109,452,000 after buying an additional 1,586,230 shares in the last quarter. Sculptor Capital LP increased its holdings in Haleon by 5.1% in the fourth quarter. Sculptor Capital LP now owns 10,454,868 shares of the company's stock worth $105,699,000 after buying an additional 505,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Haleon by 18.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 10,441,178 shares of the company's stock valued at $105,560,000 after acquiring an additional 1,589,494 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Stock Down 0.2%

Shares of HLN stock opened at $9.22 on Thursday. The stock's 50 day simple moving average is $9.82 and its 200 day simple moving average is $9.65. Haleon PLC Sponsored ADR has a twelve month low of $8.65 and a twelve month high of $11.28. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. The company has a market capitalization of $40.57 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 2.06 and a beta of 0.12.

Haleon Cuts Dividend

The business also recently declared a dividend, which will be paid on Thursday, September 17th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.0642 per share. This represents a yield of 132.0%. The ex-dividend date is Friday, August 14th. Haleon's dividend payout ratio (DPR) is 30.77%.

Analyst Ratings Changes

A number of research firms have issued reports on HLN. Jefferies Financial Group reissued a "buy" rating on shares of Haleon in a research report on Monday, August 24th. Morgan Stanley restated an "overweight" rating on shares of Haleon in a report on Thursday, August 6th. Zacks Research raised shares of Haleon from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 19th. Rothschild & Co Redburn cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a report on Tuesday, June 16th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Haleon in a report on Tuesday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy".

Haleon Company Profile

Haleon plc NYSE: HLN is a global consumer healthcare company that develops, manufactures and markets products for everyday health and wellness needs. Its portfolio spans oral health, pain relief, respiratory health, vitamins and supplements, digestive health, and therapeutic skin care.

Haleon's well-known brands include Sensodyne, Polident, parodontax, Voltaren, Panadol, Advil, Centrum, Emergen-C, Theraflu, Otrivin, Calpol, ChapStick and Excedrin. The company sells its products through pharmacies, supermarkets, mass retailers, e-commerce platforms and other healthcare channels.

Haleon was formed through the demerger of GSK's consumer healthcare business and became an independent company in 2022.

Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon PLC Sponsored ADR (NYSE:HLN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.